Canaan VII

Canaan VII is an early-stage venture capital fund managed by Canaan Partners, a firm founded in 1987 and based in San Francisco, California. Canaan Partners specializes in investing in innovative entrepreneurs, focusing primarily on the technology and healthcare sectors. The fund emphasizes investments in software and technology, media, and telecommunications. Over its 30 years of operation, Canaan has successfully managed over $5 billion in assets and completed more than 190 exits, demonstrating a strong track record in nurturing and scaling companies. With a team experienced in technology, infrastructure, communications, and life sciences, Canaan is committed to supporting promising ventures across a range of industries, ensuring it targets high-potential opportunities in the United States.

Brent Ahrens

General Partner

Brenton K. Ahrens

General Partner - West Coast

Nandu Anilal

Vice President

John Balen

Partner - West Coast

Stephen Bloch

General Partner - East Coast

Richard Boyle

General Partner - West Coast

Laura Chau

Partner

Brendan Dickinson

General Partner

Rayfe Gaspar-Asaoka

Partner

Julie Papanek Grant

General Partner

Stephen Green

Venture Partner

Wende Hutton

General Partner

Maha Ibrahim

General Partner - West Coast

Deepak Kamra

General Partner - West Coast

Nina Kjellson

General Partner - West Coast

Mark Mangiola

Venture Partner

Jared Newman

Vice President

Julie Papanek

Partner

Guy Russo

General Partner - East Coast

Timothy Shannon

General Partner

Hrach Simonian

General Partner - West Coast

Dana Warren

Venture Partner, East Coast

Bob Williams

Venture Partner - West Coast

Eric Young

Partner and Co-Founder

Past deals in Connecticut

Halda Therapeutics

Series A in 2019
Halda Therapeutics is a research-stage drug discovery company, seeking to create the next generation of precision medicine based on a novel therapeutic modality which may be a platform for a number of disease states.

Rallybio

Series A in 2018
Rallybio, LLC is a biopharmaceutical company based in New Haven, Connecticut, that focuses on developing innovative therapies for patients with severe and rare disorders. Founded in 2018, the company is dedicated to addressing life-threatening conditions, particularly through its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT). This rare disease can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's research emphasizes the development of antibody, small molecule, and engineered protein therapies, primarily in the late discovery to early clinical stages. Through its efforts, Rallybio seeks to transform the lives of patients suffering from devastating diseases.

Arvinas

Series C in 2018
Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company was founded in 2013 and is headquartered in Connecticut, United States.

Quantum Circuits

Series A in 2017
Quantum Circuits, Inc., founded in 2015 and based in New Haven, Connecticut, specializes in the development, manufacturing, and sale of quantum computers utilizing superconducting devices. The company's primary objective is to create practical and useful quantum computers, while also commercializing components, devices, and software that support fundamental research and the scaling of quantum computing. Quantum Circuits focuses on the quantum circuit model, which facilitates universal and fault-tolerant operations through error correction. The technology employs superconducting Josephson junctions that function as solid-state quantum bits, or qubits. Founded by leading experts from Yale University's Department of Applied Physics, Quantum Circuits has made significant advancements in quantum devices and information processing, contributing to notable scientific achievements, including the development of a quantum bus for entangling qubits and the execution of quantum algorithms using solid-state devices.

Arvinas

Series B in 2015
Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company was founded in 2013 and is headquartered in Connecticut, United States.

Arvinas

Series A in 2013
Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company was founded in 2013 and is headquartered in Connecticut, United States.

Marinus Pharmaceuticals

Series C in 2013
Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings. The company was founded in 2003 and is based in Branford, Connecticut.

Spine Wave

Series E in 2011
Spine Wave, Inc. manufactures and markets medical equipment for the treatment of spinal disorders. It offers expandable PEEK spacers and expandable interbody devices for posterior surgery; pivoting spacer systems; lateral spacer systems, XDL expandable devices, and lateral access systems for lateral stabilization; Leva PX, an expandable interbody device for the treatment of spinal disorders; GraftMag Graft Delivery System to deliver large amounts of bone graft; and fixation products, such as spine systems for treating degeneration, deformity, tumor, and trauma of the thoracolumbar spine, as well as adjacent level systems. The company also offers anterior cervical plate systems that provide stabilization as an adjunct to spinal fusion from C2-C7 through anterior screw fixation; and cervical spacer systems to treat degenerative disc disease from C2-T1. It offers its products through distributors. Spine Wave, Inc. was founded in 2001 and is based in Shelton, Connecticut.

Helix Therapeutics

Series A in 2010
Helix Therapeutics, Inc. develops deoxyribonucleic acid (DNA) based therapeutics. It develops novel sequence-specific gene-targeting reagents for the treatment of HIV/AIDS and common genetic diseases, such as sickle cell anemia, thalassemia, and cystic fibrosis.

Marinus Pharmaceuticals

Series B in 2009
Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings. The company was founded in 2003 and is based in Branford, Connecticut.

Sopherion

Venture Round in 2008
Sopherion Therapeutics, LLC is a privately held biopharmaceutical company based in Princeton, New Jersey, with additional offices in Cheshire, Connecticut, and Estero, Florida, as well as a subsidiary in Toronto, Canada. The company specializes in the development and commercialization of oncology therapies, notably Myocet™, a liposome-encapsulated doxorubicin-citrate complex designed to reduce cardiotoxicity. Sopherion holds an exclusive licensing agreement with Cephalon, Inc. for Myocet™ in the United States and Canada. The firm is currently conducting a Phase III global trial to evaluate Myocet™ in combination with Herceptin® and Taxol for treating invasive, metastatic breast cancer. This trial, which aims to recruit 363 patients across twelve countries, builds on promising Phase II results that demonstrated a 96% response rate and a median progression-free survival of two and a half years. Myocet™ is already registered for use in Canada and Europe in combination with cyclophosphamide for similar indications. Sopherion is also exploring additional oncology agents through its Minicell Peptide Display screening technologies.

Spine Wave

Series D in 2007
Spine Wave, Inc. manufactures and markets medical equipment for the treatment of spinal disorders. It offers expandable PEEK spacers and expandable interbody devices for posterior surgery; pivoting spacer systems; lateral spacer systems, XDL expandable devices, and lateral access systems for lateral stabilization; Leva PX, an expandable interbody device for the treatment of spinal disorders; GraftMag Graft Delivery System to deliver large amounts of bone graft; and fixation products, such as spine systems for treating degeneration, deformity, tumor, and trauma of the thoracolumbar spine, as well as adjacent level systems. The company also offers anterior cervical plate systems that provide stabilization as an adjunct to spinal fusion from C2-C7 through anterior screw fixation; and cervical spacer systems to treat degenerative disc disease from C2-T1. It offers its products through distributors. Spine Wave, Inc. was founded in 2001 and is based in Shelton, Connecticut.

Advanced BioHealing

Series C in 2007
Advanced BioHealing is an industry leader in the science of regenerative medicine. The Company is focused on the commercialization of cell-based and tissue-engineered products. It currently markets the FDA-approved product Dermagraft®, for diabetic foot ulcers. Additionally, the Company's development pipeline includes a next-generation bioengineered tissue product which is in clinical trials. ABH is a privately held company with research & development offices in New York, NY and manufacturing operations in La Jolla, CA.

Spine Wave

Series C in 2006
Spine Wave, Inc. manufactures and markets medical equipment for the treatment of spinal disorders. It offers expandable PEEK spacers and expandable interbody devices for posterior surgery; pivoting spacer systems; lateral spacer systems, XDL expandable devices, and lateral access systems for lateral stabilization; Leva PX, an expandable interbody device for the treatment of spinal disorders; GraftMag Graft Delivery System to deliver large amounts of bone graft; and fixation products, such as spine systems for treating degeneration, deformity, tumor, and trauma of the thoracolumbar spine, as well as adjacent level systems. The company also offers anterior cervical plate systems that provide stabilization as an adjunct to spinal fusion from C2-C7 through anterior screw fixation; and cervical spacer systems to treat degenerative disc disease from C2-T1. It offers its products through distributors. Spine Wave, Inc. was founded in 2001 and is based in Shelton, Connecticut.

Advanced BioHealing

Series B in 2005
Advanced BioHealing is an industry leader in the science of regenerative medicine. The Company is focused on the commercialization of cell-based and tissue-engineered products. It currently markets the FDA-approved product Dermagraft®, for diabetic foot ulcers. Additionally, the Company's development pipeline includes a next-generation bioengineered tissue product which is in clinical trials. ABH is a privately held company with research & development offices in New York, NY and manufacturing operations in La Jolla, CA.

Marinus Pharmaceuticals

Series A in 2005
Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings. The company was founded in 2003 and is based in Branford, Connecticut.

Sopherion

Series B in 2004
Sopherion Therapeutics, LLC is a privately held biopharmaceutical company based in Princeton, New Jersey, with additional offices in Cheshire, Connecticut, and Estero, Florida, as well as a subsidiary in Toronto, Canada. The company specializes in the development and commercialization of oncology therapies, notably Myocet™, a liposome-encapsulated doxorubicin-citrate complex designed to reduce cardiotoxicity. Sopherion holds an exclusive licensing agreement with Cephalon, Inc. for Myocet™ in the United States and Canada. The firm is currently conducting a Phase III global trial to evaluate Myocet™ in combination with Herceptin® and Taxol for treating invasive, metastatic breast cancer. This trial, which aims to recruit 363 patients across twelve countries, builds on promising Phase II results that demonstrated a 96% response rate and a median progression-free survival of two and a half years. Myocet™ is already registered for use in Canada and Europe in combination with cyclophosphamide for similar indications. Sopherion is also exploring additional oncology agents through its Minicell Peptide Display screening technologies.

Spine Wave

Series B in 2004
Spine Wave, Inc. manufactures and markets medical equipment for the treatment of spinal disorders. It offers expandable PEEK spacers and expandable interbody devices for posterior surgery; pivoting spacer systems; lateral spacer systems, XDL expandable devices, and lateral access systems for lateral stabilization; Leva PX, an expandable interbody device for the treatment of spinal disorders; GraftMag Graft Delivery System to deliver large amounts of bone graft; and fixation products, such as spine systems for treating degeneration, deformity, tumor, and trauma of the thoracolumbar spine, as well as adjacent level systems. The company also offers anterior cervical plate systems that provide stabilization as an adjunct to spinal fusion from C2-C7 through anterior screw fixation; and cervical spacer systems to treat degenerative disc disease from C2-T1. It offers its products through distributors. Spine Wave, Inc. was founded in 2001 and is based in Shelton, Connecticut.

Home-Link Services

Series B in 2000
Home-Link uniquely brings together your real estate broker, a Personal Move Coordinator, leading national product and service companies and the power of the Internet to make home buying, home selling and home ownership simple, convenient and more valuable.

FitLinxx

Series C in 2000
FitLinxx, Inc. specializes in wireless activity and health devices, software, and integrated data services aimed at promoting active and healthy lifestyles. The company offers a range of products, including the FitLinxx AmpStrip, a waterproof heart rate and activity tracker, and The Pebble+, an all-day activity monitor. Additionally, it provides a suite of services such as the Active Gateway API, wireless devices for weight and blood pressure monitoring, and FitLinxx SyncPoints for automatic data transmission. FitLinxx also features a fitness tracking website and mobile-friendly applications that facilitate workout tracking and communication between users and facility staff. Their products are utilized by healthcare professionals, insurers, employers, and individuals globally to enhance wellness programs, improve workforce health, and guide patients toward better health outcomes. Founded in 1993 and headquartered in Shelton, Connecticut, FitLinxx was previously known as Integrated Fitness Corporation until it rebranded in 1999.

iSolve

Venture Round in 2000
Online business-to-business integrated digital currency and barter web solution for sellers and buyers

ICON International

Venture Round in 1999
ICON International is a finance company that specializes in corporate barter services, aiming to enhance the financial performance of businesses. By focusing on the recovery of lost value from underperforming assets, ICON International enables organizations to restore value and effectively fund corporate expenses. As a subsidiary of Omnicom Group, the company provides tailored financial solutions that assist clients in optimizing their resources and improving their overall bottom line.

Tallan

Series A in 1999
For over 30 years, Tallan has been a leader in custom application development and data management, providing clients with meaningful innovations that increase operational efficiency, reduce expenditures, enhance customer experiences, and drive revenue. Tallan has advanced expertise in the areas of Portals and Collaboration, Business Intelligence, Application Integration, Mobile Platforms, User Experience, Ecommerce, Web Development, Government Solutions, Cloud Services, and IT Strategy. Tallan is one of only a select few Microsoft National Solution Providers (NSP) and has acquired multiple Gold Competencies in Microsoft technologies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.